These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12144941)

  • 21. Impaired cardiac performance in elderly patients with growth hormone deficiency.
    Colao A; Cuocolo A; Di Somma C; Cerbone G; Della Morte AM; Nicolai E; Lucci R; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1999 Nov; 84(11):3950-5. PubMed ID: 10566633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats.
    Rossoni G; De Gennaro Colonna V; Bernareggi M; Polvani GL; Müller EE; Berti F
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):260-5. PubMed ID: 9700988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction.
    Tivesten A; Bollano E; Caidahl K; Kujacic V; Sun XY; Hedner T; Hjalmarson A; Bengtsson BA; Isgaard J
    Endocrinology; 2000 Jan; 141(1):60-6. PubMed ID: 10614623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Poor correlation between pulmonary arterial wedge pressure and left ventricular end-diastolic volume after coronary artery bypass graft surgery.
    Hansen RM; Viquerat CE; Matthay MA; Wiener-Kronish JP; DeMarco T; Bahtia S; Marks JD; Botvinick EH; Chatterjee K
    Anesthesiology; 1986 Jun; 64(6):764-70. PubMed ID: 3487261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant human IGF-I does not modify the ACTH and cortisol responses to hCRH and hexarelin, a peptidyl GH secretagogue, in humans.
    Gianotti L; Ramunni J; Lanfranco F; Maccagno B; Giordano R; Broglio F; Maccario M; Muller EE; Ghigo E; Arvat E
    J Endocrinol Invest; 2001 Feb; 24(2):67-71. PubMed ID: 11263473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth hormone-independent cardioprotective effects of hexarelin in the rat.
    Locatelli V; Rossoni G; Schweiger F; Torsello A; De Gennaro Colonna V; Bernareggi M; Deghenghi R; Müller EE; Berti F
    Endocrinology; 1999 Sep; 140(9):4024-31. PubMed ID: 10465272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers.
    Frieboes RM; Antonijevic IA; Held K; Murck H; Pollmächer T; Uhr M; Steiger A
    Psychoneuroendocrinology; 2004 Aug; 29(7):851-60. PubMed ID: 15177700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of food intake in the modulation of hexarelin-induced growth hormone release in normal human subjects.
    De Marinis L; Mancini A; Valle D; Izzi D; Bianchi A; Gentilella R; Giampietro A; Desenzani P; Giustina A
    Horm Metab Res; 2000 Apr; 32(4):152-6. PubMed ID: 10824712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hexarelin, a growth hormone-releasing peptide, discloses protectant activity against cardiovascular damage in rats with isolated growth hormone deficiency.
    De Gennaro Colonna V; Rossoni G; Bernareggi M; Müller EE; Berti F
    Cardiologia; 1997 Nov; 42(11):1165-72. PubMed ID: 9534309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low dose hexarelin and growth hormone (GH)-releasing hormone as a diagnostic tool for the diagnosis of GH deficiency in adults: comparison with insulin-induced hypoglycemia test.
    Gasperi M; Aimaretti G; Scarcello G; Corneli G; Cosci C; Arvat E; Martino E; Ghigo E
    J Clin Endocrinol Metab; 1999 Aug; 84(8):2633-7. PubMed ID: 10443652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beneficial hemodynamic and renal effects of intravenous enalaprilat following coronary artery bypass surgery complicated by left ventricular dysfunction.
    Wagner F; Yeter R; Bisson S; Siniawski H; Hetzer R
    Crit Care Med; 2003 May; 31(5):1421-8. PubMed ID: 12771613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hexarelin, a growth hormone secretagogue, protects the isolated rat heart from ventricular dysfunction produced by exposure to calcium-free medium.
    Rossoni G; Locatelli V; Gennaro Colonna Vd ; Müller EE; Berti F
    Pharmacol Res; 2000 Aug; 42(2):129-36. PubMed ID: 10887041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of growth hormone-releasing activity of hexarelin in man.
    Arvat E; Gianotti L; Di Vito L; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
    Neuroendocrinology; 1995 Jan; 61(1):51-6. PubMed ID: 7731498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.
    Arvat E; Maccagno B; Ramunni J; Gianotti L; Di Vito L; Deghenghi R; Camanni F; Ghigo E
    J Endocrinol Invest; 1997 Mar; 20(3):122-7. PubMed ID: 9186817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study.
    Anastasiadis K; Antonitsis P; Vranis K; Kleontas A; Asteriou C; Grosomanidis V; Tossios P; Argiriadou H
    Interact Cardiovasc Thorac Surg; 2016 Nov; 23(5):740-747. PubMed ID: 27378790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Usefulness of left ventricular stroke volume variation to assess fluid responsiveness in patients with reduced cardiac function.
    Reuter DA; Kirchner A; Felbinger TW; Weis FC; Kilger E; Lamm P; Goetz AE
    Crit Care Med; 2003 May; 31(5):1399-404. PubMed ID: 12771609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intracoronary shunts reduce transient intraoperative myocardial dysfunction during off-pump coronary operations.
    Yeatman M; Caputo M; Narayan P; Ghosh AK; Ascione R; Ryder I; Angelini GD
    Ann Thorac Surg; 2002 May; 73(5):1411-7. PubMed ID: 12022525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects.
    Bellone J; Bartolotta E; Sgattoni C; Aimaretti G; Arvat E; Bellone S; Deghenghi R; Ghigo E
    J Endocrinol Invest; 1998 Sep; 21(8):494-500. PubMed ID: 9801989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency.
    Longobardi S; Cuocolo A; Merola B; Di Rella F; Colao A; Nicolai E; Cardei S; Salvatore M; Lombardi G
    Clin Endocrinol (Oxf); 1998 Feb; 48(2):137-43. PubMed ID: 9579223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin).
    Laron Z; Frenkel J; Gil-Ad I; Klinger B; Lubin E; Wuthrich P; Boutignon F; Lengerts V; Deghenghi R
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):539-41. PubMed ID: 7955465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.